Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 15/20 | 0.51 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338498 | 1.00 | GRM2 (0.51) | GRM2GRM7SPHK2AXLTYRO3 | |
| SCHEMBL1339262 | 1.00 | GRM2 (0.51) | GRM2GRM7SPHK2AXLTYRO3 | |
| SCHEMBL1338801 | 0.89 | GRM2 (0.43) | GRM2GRM7SPHK2 | |
| SCHEMBL1339289 | 0.88 | GRM2 (0.40) | GRM2GRM7SPHK2 | |
| SCHEMBL1339105 | 0.88 | GRM2 (0.40) | GRM2GRM7SPHK2 | |
| SCHEMBL1339104 | 0.88 | GRM2 (0.40) | GRM2GRM7SPHK2 | |
| SCHEMBL1339020 | 0.88 | GRM2 (0.51) | GRM2GRM7 | |
| SCHEMBL1339018 | 0.88 | GRM2 (0.51) | GRM2GRM7 | |
| SCHEMBL1339054 | 0.85 | GRM2 (0.54) | GRM2GRM7 | |
| SCHEMBL1339053 | 0.85 | GRM2 (0.54) | GRM2GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346505-B1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | claimed |
| US-8697689-B2 | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-15 | — | — | US | claimed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | claimed |
| EP-2346505-B1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8697689-B2 | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-15 | — | — | US | disclosed |
| CN-102186477-B | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors | ORTHO MCNEIL JANSSEN PHARM | 2013-07-17 | — | — | CN | disclosed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | disclosed |
| CN-102186477-A | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors | ORTHO MCNEIL JANSSEN PHARM | 2011-09-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM1, GRM5 | GRM2 1/4885GRM7 10/4885SPHK2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.